Hospital

New indications include Staphylococcus aureus bloodstream (SAB) infections, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia.

The results indicate the need for targeted policies so that biosimilar competition can increase cost savings and affordability for patients with commercial insurance.

This medication is associated with a number of adverse effects, such as gastrointestinal upset and peripheral neuropathies, that may be mitigated by less frequent dosing.

The decision follows phase 3 trial results that demonstrated improved progression-free survival and confirmed the safety of Dato-DXd in patients with breast cancer.

By implementing easier systems of education for patients, the consequences of polypharmacy could potentially decrease.

Positive phase 3 trial results showed that danicopan was more effective than placebo when treating extravascular hemolysis in paroxysmal nocturnal hemoglobinuria.

Scientists hypothesize that fecal microbiota transplant restores the recipient’s gut microbiota to an environment that mimics the healthy donor’s microbiota

However, investigators found that the prevalence of Streptococcus pneumoniae nasopharynx-oropharynx colonization was higher among younger adults.

Interactions between nirmatrelvir/ritonavir and direct oral anticoagulants is complicated, and a point of contrasting views between the US and EU medical communities.

An overview of the use of direct oral anticoagulants as an alternative to warfarin in the treatment of left ventricular thrombus.

The recent ODD for the utidelone injectable could offer another treatment option for patients with BCBM.

The mutations, C594Y and P735R, were found in the GNE gene and may influence sialylation, a process that is crucial for brain development.

Pediatric patients with the variant were approximately 1.44 times more likely develop ALL compared with children who do not have the variant.

Investigators found that mRNA technology for the delivery of antibody therapeutics were used to target tau in Alzheimer disease and can be applied to other tau targets.

The ODD comes after AP303 presented meaningful improvements in renal survival in an ADPKD and the completion of the first study that evaluated healthy human participants.

As the full act will be enforced in November 2024, all medication dispensers must ensure they’re fully prepared.

The results displayed a dramatic reduction in the individuals’ tumors within days after single treatment.

Calder’s 3D Vaxlock technology attained 11 times more effective immune response, compared to typical comparator.

The authors believe that pancreatic enzyme therapy has potential in managing patient symptoms, altering the disease course, and the development of standardized care.

A study that analyzed data from 2000 to 2021 indicated improvements for both leukemia-free survival and overall survival for older patients with acute myeloid leukemia.

All 20 participants in a 12-month follow-up study attained acute success from ablation procedures.

Early treatment administration with this regimen also promoted a faster decrease in viral load and shorter viral shedding in patients with hematologic diseases who were positive for COVID-19.

The test scans whole blood samples from individual human donors for the 5 parasite species that can cause malaria in humans and detects Plasmodium RNA and DNA.

In December 2023, nipocalimab (Johnson & Johnson) was granted orphan drug designation for fetal neonatal alloimmune thrombocytopenia.

Pharmacists play a pivotal role working alongside the DEA and OIG in enforcing and preventing drug diversion nationally.

Previously, felzartamab received orphan drug designation and breakthrough therapy designation for the treatment of primary membranous nephropathy.

The orphan drug designation (ODD) comes after positive results from a phase 2 trial that showed cevidoplenib improved platelet counts by 63.6% and 40.9% in 2 different dose groups.

Zero relapses were reported among individuals that received ravulizumab-cwvz over the 73 weeks of treatment.